Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.

It is the latest in a string of alliances announced by Boehringer in the NASH area in recent years, coming after earlier deals with Dicerna and MiNA Therapeutics – which both involved RNA-based ...